GlassScriptPhysician profile
Erik S Little
NPI 1558464560
$10,584.02
in general payments reported to CMS, 2019-2025
50 companies · $2,527 in 2025
The $2,527 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $819 · 2022: $2,277 · 2023: $2,589 · 2024: $2,372 · 2025: $2,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,487.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,677.48 | 2021-2025 | |
| Lilly USA, LLC | $1,023.68 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $890.00 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $883.81 | 2021-2025 | Jardiance, Stiolto Respimat, Synjardy |
| Pfizer INC. | $576.20 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $556.47 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $532.91 | 2021-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $497.23 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $342.32 | 2022-2025 | |
| Ibsa Pharma INC. | $220.80 | 2022-2025 | Tirosint, Licart, Licart |
| Abbott Laboratories | $206.17 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Biohaven Pharmaceutical Holding Company LTD. | $205.42 | 2022 | |
| Janssen Pharmaceuticals, INC | $201.83 | 2022-2025 | Spravato, Xarelto |
| Teva Pharmaceuticals USA, INC. | $191.18 | 2022-2025 | Austedo Xr, Austedo Xr, Airduo Digihaler |
| Dexcom, INC. | $172.37 | 2022-2025 | Dexcom G6 Transmitter |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Little listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.